UK markets close in 2 hours 27 minutes
  • FTSE 100

    6,647.40
    -28.07 (-0.42%)
     
  • FTSE 250

    21,423.59
    -12.73 (-0.06%)
     
  • AIM

    1,176.54
    -12.35 (-1.04%)
     
  • GBP/EUR

    1.1597
    +0.0035 (+0.30%)
     
  • GBP/USD

    1.3959
    +0.0007 (+0.05%)
     
  • BTC-GBP

    35,579.44
    -2,216.78 (-5.87%)
     
  • CMC Crypto 200

    995.08
    +7.87 (+0.80%)
     
  • S&P 500

    3,819.72
    -50.57 (-1.31%)
     
  • DOW

    31,270.09
    -121.43 (-0.39%)
     
  • CRUDE OIL

    62.40
    +1.12 (+1.83%)
     
  • GOLD FUTURES

    1,713.40
    -2.40 (-0.14%)
     
  • NIKKEI 225

    28,930.11
    -628.99 (-2.13%)
     
  • HANG SENG

    29,236.79
    -643.63 (-2.15%)
     
  • DAX

    14,061.05
    -18.98 (-0.13%)
     
  • CAC 40

    5,828.66
    -1.40 (-0.02%)
     

Why Regeneron (REGN) Could Beat Earnings Estimates Again

Zacks Equity Research
·3-min read

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Regeneron (REGN), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.

When looking at the last two reports, this biopharmaceutical company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 15.28%, on average, in the last two quarters.

For the last reported quarter, Regeneron came out with earnings of $8.36 per share versus the Zacks Consensus Estimate of $7.23 per share, representing a surprise of 15.63%. For the previous quarter, the company was expected to post earnings of $6.23 per share and it actually produced earnings of $7.16 per share, delivering a surprise of 14.93%.

With this earnings history in mind, recent estimates have been moving higher for Regeneron. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Regeneron currently has an Earnings ESP of +0.15%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner.

With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss.

Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research